TY - JOUR
T1 - A pragmatic approach to the use of inotropes for the management of acute and advanced heart failure
T2 - An expert panel consensus
AU - Farmakis, Dimitrios
AU - Agostoni, Piergiuseppe
AU - Baholli, Loant
AU - Bautin, Andrei
AU - Comin-Colet, Josep
AU - Crespo-Leiro, Maria G.
AU - Fedele, Francesco
AU - García-Pinilla, Jose Manuel
AU - Giannakoulas, George
AU - Grigioni, Francesco
AU - Gruchała, Marcin
AU - Gustafsson, Finn
AU - Harjola, Veli Pekka
AU - Hasin, Tal
AU - Herpain, Antoine
AU - Iliodromitis, Efstathios K.
AU - Karason, Kristjan
AU - Kivikko, Matti
AU - Liaudet, Lucas
AU - Ljubas-Maček, Jana
AU - Marini, Marco
AU - Masip, Josep
AU - Mebazaa, Alexandre
AU - Nikolaou, Maria
AU - Ostadal, Petr
AU - Põder, Pentti
AU - Pollesello, Piero
AU - Polyzogopoulou, Eftihia
AU - Pölzl, Gerhard
AU - Tschope, Carsten
AU - Varpula, Marjut
AU - von Lewinski, Dirk
AU - Vrtovec, Bojan
AU - Yilmaz, Mehmet Birhan
AU - Zima, Endre
AU - Parissis, John
PY - 2019/12/15
Y1 - 2019/12/15
N2 - Inotropes aim at increasing cardiac output by enhancing cardiac contractility. They constitute the third pharmacological pillar in the treatment of patients with decompensated heart failure, the other two being diuretics and vasodilators. Three classes of parenterally administered inotropes are currently indicated for decompensated heart failure, (i) the beta adrenergic agonists, including dopamine and dobutamine and also the catecholamines epinephrine and norepinephrine, (ii) the phosphodiesterase III inhibitor milrinone and (iii) the calcium sensitizer levosimendan. These three families of drugs share some pharmacologic traits, but differ profoundly in many of their pleiotropic effects. Identifying the patients in need of inotropic support and selecting the proper inotrope in each case remain challenging. The present consensus, derived by a panel meeting of experts from 21 countries, aims at addressing this very issue in the setting of both acute and advanced heart failure.
AB - Inotropes aim at increasing cardiac output by enhancing cardiac contractility. They constitute the third pharmacological pillar in the treatment of patients with decompensated heart failure, the other two being diuretics and vasodilators. Three classes of parenterally administered inotropes are currently indicated for decompensated heart failure, (i) the beta adrenergic agonists, including dopamine and dobutamine and also the catecholamines epinephrine and norepinephrine, (ii) the phosphodiesterase III inhibitor milrinone and (iii) the calcium sensitizer levosimendan. These three families of drugs share some pharmacologic traits, but differ profoundly in many of their pleiotropic effects. Identifying the patients in need of inotropic support and selecting the proper inotrope in each case remain challenging. The present consensus, derived by a panel meeting of experts from 21 countries, aims at addressing this very issue in the setting of both acute and advanced heart failure.
KW - Acute heart failure
KW - Advanced heart failure
KW - Dobutamine
KW - Inodilators
KW - Inotropes
KW - Levosimendan
KW - Milrinone
KW - Norepinephrine
UR - http://www.scopus.com/inward/record.url?scp=85073246355&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85073246355&partnerID=8YFLogxK
U2 - 10.1016/j.ijcard.2019.09.005
DO - 10.1016/j.ijcard.2019.09.005
M3 - Article
C2 - 31615650
AN - SCOPUS:85073246355
VL - 297
SP - 83
EP - 90
JO - International Journal of Cardiology
JF - International Journal of Cardiology
SN - 0167-5273
ER -